


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Pier
 Serial No: 09/405,735
 Filed: September 24, 1999
 For: METHODS AND PRODUCTS FOR TREATING PSEUDOMONAS
 INFECTION
 Examiner: Unassigned
 Art Unit: 1646



CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231, on the 18th day of January, 2000.

Kim Ray-Akeeli

Assistant Commissioner for Patents
 Washington, D.C. 20231

PRELIMINARY AMENDMENT

Sir:

Before calculating the filing fee, please amend claims 9-13, 22-25, 34, 52-53, and 60-61 as follows:

B1
 9. (Amended) The method of claim[s] 1 [-8] wherein the subject has a condition predisposing the subject to a *Pseudomonal* infection.

10. (Amended) The method of claim[s] 1 [-8] wherein the subject has a *Pseudomonal* infection.

11. (Amended) The method of claim[s] 1 [-8] wherein the subject has a defective cystic fibrosis transmembrane conductance regulator gene.

12. (Amended) The method of claim[s] 1 [-8] wherein the polysaccharide is administered systemically to the subject.

13. (Amended) The method of claim[s] 1 [-8] wherein the polysaccharide is administered by inhalation to the subject.

B2
22. (Amended) The pharmaceutical preparation of claim[s] 14 [-21] wherein the pharmaceutical preparation is sterile.

23. (Amended) The pharmaceutical preparation of claim[s] 14 [-21] wherein the pharmaceutical preparation is formulated in a unit dosage in an amount effective for treating *Pseudomonas* infection.

24. (Amended) The pharmaceutical preparation of claim[s] 14 [-21] wherein the pharmaceutical preparation is formulated as an aerosol for inhalation.

25. (Amended) The pharmaceutical preparation of claim[s] 14 [-21] wherein the pharmaceutical preparation is formulated as an injectable preparation.

B3
34. (Amended) The composition of matter of claim[s] 26 [-33] wherein the lipid has the following structural formula: $\text{CH}_3(\text{CH}_2)_n\text{COOH}$ wherein n=1-50.

B4
52. (Amended) The method of claims 44 [-51] wherein the bioactive agent is covalently coupled to the polysaccharide.

53. (Amended) The method of claim[s] 44 [-51] wherein the bioactive agent is contained in a liposome comprising a lipid biocompatible with a human subject, and wherein the polysaccharide is covalently coupled to the lipid.

B5
60. (Amended) The composition of claim[s] 54 [-59] wherein the anti-*Pseudomonas* drug is an antibiotic.

61. (Amended) The composition of claim[s] 54 [-59] wherein the anti-*Pseudomonas* drug is selected from the group consisting of Amifloxacin; Amifloxacin Mesylate; Amikacin; Amikacin Sulfate; Aminosalicylic acid; Aminosalicylate sodium; Azlocillin; Azlocillin Sodium; Bacampicillin Hydrochloride; Carbenicillin Disodium; Carbenicillin Indanyl Sodium; Carbenicillin Phenyl Sodium; Carbenicillin Potassium; Carumonam Sodium; Cefaclor; Cefadroxil; Cefamandole; Cefamandole Nafate; Cefamandole Sodium; Cefaparole; Cefatrizine; Cefazoflur Sodium; Cefazolin; Cefazolin Sodium; Cefbuperazone; Cefdinir; Cefepime; Cefepime Hydrochloride; Cefetecol; Cefixime; Cefmenoxime Hydrochloride; Cefmetazole; Cefmetazole Sodium; Cefonicid Monosodium; Cefonicid Sodium; Cefoperazone Sodium; Ceforanide; Cefotaxime Sodium; Cefotetan; Cefotetan Disodium; Cefotiam Hydrochloride; Cefoxitin; Cefoxitin Sodium; Cefpimizole; Cefpimizole Sodium; Cefpiramide; Cefpiramide Sodium; Cefpirome Sulfate; Cefpodoxime Proxetil; Cefprozil; Cefroxadine; Cefsulodin Sodium; Ceftazidime; Ceftibuten; Ceftizoxime Sodium; Ceftriaxone Sodium; Cefuroxime;

*Cox
B5*

Cefuroxime Axetil; Cefuroxime Pivoxetil; Cefuroxime Sodium; Cephacetrile Sodium;
Cephalexin; Cephalexin Hydrochloride; Cephaloglycin; Cephaloridine; Cephalothin Sodium;
Cephapirin Sodium; Cephradine; Cetocycline Hydrochloride; Cetophenicol; Chlortetracycline
Bisulfate ; Chlortetracycline Hydrochloride ; Ciprofloxacin; Ciprofloxacin Hydrochloride;
Colistin Sulfate; Coumermycin; Coumermycin Sodium; Doxycycline; Doxycycline Calcium;
Doxycycline Fosfate; Doxycycline Hyclate; Droxacin Sodium; Enoxacin; Epicillin;
Epitetracycline Hydrochloride; Imipenem; Kanamycin Sulfate; Meclocycline; Minocycline;
Minocycline Hydrochloride; Nafcillin Sodium; Norfloxacin; Ofloxacin; Oxytetracycline;
Oxytetracycline Calcium; Piperacillin Sodium; Pirbenicillin Sodium; Tetracycline; Tetracycline
Hydrochloride ; Tetracycline Phosphate Complex; Ticarcillin Cresyl Sodium; Ticarcillin
Disodium; Ticarcillin Monosodium; Tobramycin, and Tobramycin Sulfate.

Respectfully submitted,



Helen C. Lockhart
Reg. No. 39,248
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, MA 02210-2211
(617)720-3500

Docket No.B0801/7155
January 18, 2000
X1/18/00